Anti-integrin antibodies, compositions, methods and uses

Details Anti-integrin antibodies, compositions, methods and uses Anti-integrin antibodies, compositions, methods and uses

2009-04-21

2011-12-06

Haddad, Maher (Department: 1644)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S326000, C435S252300, C435S320100, C435S455000

Reexamination Certificate

active

08071333

ABSTRACT:
The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

REFERENCES:
patent: 5674483 (1997-10-01), Tu et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5877397 (1999-03-01), Lonberg et al.
patent: 5985278 (1999-11-01), Mitjans et al.
patent: 6171588 (2001-01-01), Carron et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6359126 (2002-03-01), Kim et al.
patent: 6369204 (2002-04-01), Kim et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 2001/0011125 (2001-08-01), Huse
patent: 2003/0143603 (2003-07-01), Giles-Komar et al.
patent: 0260829 (1988-03-01), None
patent: 719859 (1996-07-01), None
patent: 0834557 (2005-06-01), None
patent: WO 93/20229 (1993-10-01), None
patent: WO 94/12181 (1994-06-01), None
patent: WO 95/25543 (1995-09-01), None
patent: WO 97/06791 (1997-02-01), None
patent: WO 97/36859 (1997-10-01), None
patent: WO 0031248 (2000-06-01), None
patent: WO 0044404 (2000-08-01), None
Trikha et al., CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer: 110, 326-335 (2004)).
Mitjans et al, “In Vivo Therapy of Malignant Melanoma by Means of Antagonists of av Integrins,” Int. J. Cancer, 2000, pp. 716-723, vol. 87, Wiley-Liss, Inc., Spain.
Mitjans et al, “An anti-av-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice,” Journal of Cell Science, 1995, pp. 2825-2838, vol. 108, The Company of Biologists Limited, Great Britain.
Casel et al, “RGD Peptides and Monoclonal Antibodies, Antagonists of av-integrin, Enter the Cells by Independent Endocytic Pathways,” Laboratory Investigation, 2001, pp. 1615-1626, vol. 81, No. 12, The United States and Canadian Academy of Pathology, Inc., USA.
Tam et al, “Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates equivalent affinity and functional blockage of glycoprotein Lib/IIIa and Avβ3Integrins,” vol. 98, No. 11, Sep. 15, 1998, pp. 1089-1091, USA.
Trikha et al, “A potential new application for a cardiovascular drug: Role for ReoPro (Abciximab) an inhibitor of GBIIB/IIIA and alphaVbeta3 integrins as an anti-cancer agents,” Proceedings of the American Association for Cancer Research, vol. 41, Mar. 2000, p. 577, USA.
Sukuki et al, “cDNA and amino acid sequences of the cell adhesion protein receptor recognizing vitronectin reveal a transmembrane domain and homologies with other adhesion protein receptors,” Cell Biology, Nov. 1986, pp. 8614-8618, vol. 83, Proc. National Academy Science, USA.
Lehmann et al, “A monoclonal antibody inhibits adhesion to fibronectin and bitronectin of a colon carcinoma cell line and recognizes the integrins αvβ3αvβ5αvβ,” Cancer Research, 1994, pp. 2102-2107, vol. 54, USA.
Gunther Castl, Thomas Hermann, Michael Steurer, Jorg Zmija, Eberhard Gunsilius, Clemens Unger, and Andrea Kraaft, “Angiogenesis as a target for tumor treatment,” Oncology, 1997, 177-84, vol. 54.
Brian P. Eliceiri and David A. Cheresh, “The role of alpha-v integrins during angiogenesis: insights into potential mechanisms of action and clinical development,” The Journal of Clinical Investigation, May 1999, pp. 1227-1230, vol. 103, No. 9.
Martin Friedlander, Peter C. Brooks, Robert W. Shaffer, Christine M. Kincaid, Judith A. Varner and David A. cherish, “Definition of Two Angiogenic Pathways by Distinct Alpha-V Integrins,” Science, Dec. 1, 1995, 1500-2. vol. 270.
Lisa D. Taylor, Condie E. Carmack, Dennis Huszar, Kay M. Higgins, Roshanak Mashayekh, Getachew Sequar, Stephen R. Schramm, Chiung-Chi Kuo, Susan L. O'Donnell, Robert M. Kay, Olive S. Woodhouse and Nils Lonberg, “Human immunoglobulin transgenes undergo rearrangement, somatic mutuation and class switching in mice that lack endogenous IgM,” International Immunology., 1994; 579-91, vol. 6, No. 4, Oxford University Press.
Nils Lonberg, Lisa D. Taylor, Fiona A. Harding, Mary Trounstine, Kay M. Higgins, Stephen R. Schramm, Chiung-Chi Kuo, Roshanak Masayekh, Kathryn Wymore, James G. McCabe, Donna Munoz-O'Regan, Susan L. O'Donnell, Elizabeth S. G. Lapachet, Tash Bengoechea, Dianne M. Fishwild, Condie E. Carmack, Robert M. Kay and Dennis Huszar “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, Apr. 28, 1994, pp. 856-859, vol. 368.
Michael Neuberger, “Generating high-avidity human Mabs in mice,” Nature Biotechnology, Jul. 1996, 826, vol. 14.
Dianne M. Fishwild, Susan L. O'Donnell, Tash Bengoechea, Debra V. Hudson, Fiona Harding, Susan L. Bernhard, Debbie Jones, Robert M. Kay, Kay M. Higgins, Stephen R. Schramm and Nils Lonberg, “High-avidity human IgG-kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology, Jul. 1996, 845-51, vol. 14.
Elizabeth A. Wayner, Robert A. Orlando and David A. Cheresh, “Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to Vitronectin but Differently Distribute on the Cell Surface,” J. Cell Biology, May 1991, 919-929, vol. 113, No. 4.
John F. Marshall, Deborah C. Rutherford, Alison C.E. McCartney, Francesc Mitjans, Simon L. Goodman and Ian R. Hart, “Alpha v beta 1 is a receptor for bitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin,” J. of Cell Science, 1995, pp. 1227-1238, vol. 108.
David A. Cheresh and Robert C. Spiro, “Biosynthetic and Functional Properties of an Arg-Gly-Asp-directed Receptor Involved in Human Melanoma Cell Attachment to Bitronectin, Fibrinogen, and von Willebrand Factor,” J. of Biological Chemistry, Dec. 25, 1987, pp. 17703-17711, vol. 262, No. 36.
Hans Kemperman, Yvonne M. Wijnands, and Ed Roos, “Alpha v integrins on HT-29 Colon Carcinoma Cells: Adhesion to Fibronectin is Mediated Solely by Small Amounts of Alpha va Beta 6, and alpha v beta 5 is Codistributed with Actin Fibers,” Experimental Cell Research, 1997, pp. 156-164, vol. 234.
Friedlander et al, “Involvement of integrins avB3 and avB5 in ocular neovascular diseases,” Pro. Natl Acad., Science, 1996, pp. 9764-9769, vol. 93, USA.
Larry L. Green, Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. Journal of Immunological Methods, vol. 231, Dec. 1999, pp. 11-23.
David J. Panka et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies”,Proc. Natl Acad. SciUSA, vol. 85, pp. 3080-3084, May 1988.
A.G. Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 angstrom Resolution”Science, New Series, vol. 233, No. 4765, pp. 747-753, Aug. 15, 1986.
Jirou Orihara, Sensitizing Capacity, Cross-reactivity and Antigenic Determinants of Bisphenals AThe Journal of Stomatological Society, vol. 59, No. 2, pp. 439-455, Jun. 1992, XP-002278171, English Abstract Only.
Montserrat Castillo et al., “Analysis of industrial effluents to determine endocrine-disrupting chemicals”,Trends in Analytical Chemistry, vol. 16, No. 10, p. 574-583 1997.
Jordi Gascon et al., “Detection of endocrine-disrupting pesticides by enzyme-linked immunosorbent assay (ELISA): application to atrazine”,Trends in Analytical Chemistry, vol. 16, No. 10, pp. 554-562, 1997.
Elizabeth A. Wayner, et al., “Integrins avB3 and avB5 Contribute to Cell Attachment to Vitronectin but Differentially Distribute on the Cell Surface”,J. Cell Biol., vol. 113(4), pp. 919-929 May 1991.
Chemicon International Catalo

Affiliated with

Also associated with

Rating

Anti-integrin antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-integrin antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-integrin antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4294066